Special focus on
- Prostate Cancer
- M.D., George Washington University, 0 2003
- Internal medicine, Oregon Health & Science University, 2006
- Hematology and medical oncology, Oregon Health & Science University, 2009
- American Board of Internal Medicine, 2006
Dr. Graff specializes in prostate cancer care. She trained under Dr. Tomasz Beer, a well-known prostate cancer researcher and clinician. Her research interests include determining how some prostate cancers resist chemotherapy drugs. She recently presented her research findings at the annual meeting of the American Association for Cancer Research. She has also designed a clinical trial examining the use of immunotherapy early in metastatic prostate cancer. Dr. Graff enjoys dividing her time between caring for the country's veterans at the Portland VA Medical Center and seeing patients at Oregon Health & Science University. Dr. Graff is also a volunteer at the Wallace Medical Concern, an urgent care clinic for the uninsured. She and her husband watch many movies and enjoy eating out. She is an avid reader and also writes short stories.
OHSU Connections article
Clinical trials offer new hope for advanced prostate cancer
- Spanish (some)
Memberships and associations
- American Society of Clinical Oncology
The following clinical trials are currently accepting new participants:
- A Phase II Study of CTLA Blockade by Ipilimumab, with and without Radiation Therapy, in Patients with an Incomplete Response to Androgen Suppression Therapy for Metastatic Prostate Cancer
- A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
- A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer
- A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
- PVAMC / OHSU J: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
4.9 out of 5 (113 Ratings, 26 Comments)
The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys.
- Nov 02, 2018
Julie is thorough, compassionate, intelligent, takes time to listen, addresses all your concerns and needs, and overall, is an outstanding physician. Thank you.
- Nov 01, 2018
- Oct 25, 2018
Professional, empathetic and caring! You can't ask for more in a Doctor!
- Oct 12, 2018
Dr was very personable and informative.
- Oct 04, 2018
Dr. Graff is a very caring, very professional outstanding physician. I feel extremely fortunate to have her in charge of my care team for my clinical trial.
- Sep 19, 2018
Always interested, always concerned, professional in every way.
- Sep 12, 2018
Knowledgeable, polite, kind, caring.
- Sep 12, 2018
Knowledgeable Doctor, kind and caring. A good listener too!
- Sep 07, 2018
Very helpful provider.
- Sep 07, 2018
I really liked meeting with Julie. She's ? really good at what she does, very empathetic and a great doctor and researcher. I appreciate her help.